Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lemborexant in Hepatic Impairment
NCT03440424Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lemborexant in Insomnia (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Plasma Concentration at Day 1, Area Under the Plasma Concentration-Time Curve (0-8h) at Day 1 and 3 more. Started Jan 2018; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03440424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03440424.